0:03
David Lou here as part of RheumNow's coverage of ACR 2026.
0:08
It's been a big meeting. I just wanted to bring you some of the CAR-T content.
0:13
Something that caught my eye was actually a poster from the Mayo, looking at something that's come up before, which is this idea that maybe we might get new rheumatic disease after CAR-T, might get immune-related adverse events after CAR-T.
0:31
Now there's been a Spanish report about some of this a while back.
0:39
Obviously we have limited our numbers in terms of rheumatic or autoimmune disease CAR-T, but in oncology they've been using CAR-T for some time — well, more years than us — and so actually this is the opportunity to look back and see how they've gone.
0:53
Have those patients developed immune-related adverse events, new rheumatic disease?
0:59
So this Mayo cohort looked at 1,335 conventional CAR-T patients and looked to see what the rates were from that.
1:12
So out of those, 17 developed new onset autoimmune disease.
1:16
So that's 1.27%. The previous Spanish estimate was just below 2%.
1:21
So really in that same ballpark. So not a massive number — certainly a lot less than what you see with immune checkpoint inhibitors.
1:28
And I think critically as well, when you break that down, about half of them were the non-ICANS immune-mediated neurotoxicity.
1:37
So, neurotoxicity — not our classic rheumatic diseases.
1:41
When you break it down out of the 1,335, when you break down to the 17, we saw four had sarcoid, four had a seronegative inflammatory arthritis, and one each in PMR and GCA.
1:56
So in amongst that, you know, causality is always really hard to determine in these situations.
2:02
I think as well, even though 1,335 sounds like a lot of patients, when you're looking at these relatively rare things it's very hard to determine patterns off of what are still small numbers.
2:16
But we're really seeing something which is very different to immune checkpoint inhibitors.
2:19
You know, this might be all part of — I guess — lymphocyte expansion, cell population expansion in CAR-T, and that might be driving it.
2:31
But fundamentally it's a lot less phenotypic, a lot less structured.
2:35
It's something which is not the same, and it's a lot less common than immune checkpoint inhibitors.
2:41
It's definitely a much more dispersed phenotype, and I don't think it's going to be as much of a problem — by many orders of magnitude — compared to immune checkpoint inhibitors and immune-related adverse events there.
2:56
So for plenty more on our CAR-T content, you know where to go — RheumNow.com.
If you are a health practitioner, you may Login/Register to comment.
Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.